Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Global Markets for Vaccine Technologies

Enquire | Email | Print

Single User - $6,650       2 to 5 Users - $8,500       6 to 10 Users - $10,500       11to 20 Users - $12,500       21+ Users - $15,000
Published Date: Jul, 2013
Format: PDF
No of Pages: 199

 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

REPORT HIGHLIGHTS

This report provides:

-An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies.
Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
-Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines.
-A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers.
-Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.

INTRODUCTION

STUDY OBJECTIVES


This BCC study assesses and analyzes advancements in the human and animal vaccine industry. The report discusses the current dynamics of the vaccine market and predicts the future market growth based on factors such as current products, trends in the strategic moves of multinational companies, market share, product pipelines, consumer behavior and the immunization strategies of various governmental and non-governmental organizations. This study also examines the key aspect of health safety for both human and animal vaccination programs.

The report presents the present market and its potential for growth, including revenue estimations, product types/categories, market leaders, market shares and factors and drivers influencing the market for human and animal vaccines. In addition, the report summarizes the scientific platforms, innovations, top-selling products and prospective candidates for the present and future market. Vaccine market trends, coverage plans by key vaccine regulatory bodies, patents and health safety concerns are also presented in the report. The opportunities and challenges presented to vaccine manufacturers and government bodies, especially in the developing countries, are discussed within this report.

The report presents the sales data of vaccine manufacturing companies and other relevant sources where available. The vaccine market is analyzed by types or categories for human and animal vaccines for the period of 2010 to 2012. In addition, revenue projections are given for 2017. The report also presents data on regional sales of vaccines in North America (the U.S. and Canada), Europe and the emerging markets.

REASONS FOR DOING THIS STUDY

The progress in the vaccine industry from the perspective of usage, coverage, awareness and innovation over the past decade has been noteworthy. The study covers the latest industry developments for human and animal vaccines, including updates on financial, scientific, research and new product developments. Human vaccines offer a solution to improving health worldwide. The report offers companies an analysis that they can use in strategizing their immunization plans going forward.

The latest market trends, including mergers/joint ventures, market penetration of large companies in the ever-growing developing markets, research, changing consumer preferences, health and safety awareness and immunization coverage campaigns are driving the vaccine market. These trends are opening up diverse opportunities for manufacturers and scientists to develop innovative and affordable products. This study summarizes these factors for both the human and animal vaccine industries.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This study emphasizes the necessity of vaccines in ensuring the health of both humans and animals. For human vaccines, the focus is on the developing countries where access to vaccines is badly needed. For animals, vaccination is a health safety requirement to ensure the health of animals and to avoid the transference of diseases from animals to humans, for both food producing animals and companion animals. The study offers an overview of the vaccine industry for market participants such as manufacturers, researchers and non-governmental organizations.

SCOPE OF THE STUDY

The report studies the various factors impacting the global market for human and animal vaccines. BCC conducted a market evaluation for vaccine types/categories for humans and animals, including their respective regional sales, applications, regulatory aspects, market forecasts, prospects, innovation and challenges, patent analyses, clinical trials, market leaders and market shares of vaccine sales.

The data gathered is for the global markets and statistically validated for the current and forecasted values. Similar techniques were applied for regional data measurements and sales in the respective regions studied. Product details and scientific techniques/platforms are provided based on their commercial and industrial viability.

The emerging markets for orphan drugs include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY

BCC employed both primary as well as secondary research methodologies to gather relevant information on the vaccine industry. In order to do that, BCC interviewed industry veterans, including scientists, manufacturers and others as well as conducted relevant searches, including pharmaceutical and vaccine related newsletters, blogs, papers, journals, technical blogs, digests, news feeds, technical articles, company white papers, research papers and other sources. Market projections reflect estimated unit prices, vaccine usage and potential immunization coverage, the present market economy, future application of vaccines and market direction and trends.

INFORMATION SOURCES

BCC researched companies associated with the vaccine industry to acquire data for this study. These companies were mostly manufacturers and end users of vaccines for both humans and animals. BCC contacted industry representatives of vaccine companies, scientists and research teams to gain better insight into the prospects and development of the industry.

In addition, BCC consulted scientific papers, research papers and articles, science journal, medical and pharmaceutical papers and journals, company white papers, financial reports, newsletters, company literature, medical and pharmaceutical blogs, product literature, technical articles, periodicals, bulletins, abstracts, regulations, patent files, etc. Pharmaceutical and medical related database searches were also key contributors for the research work.

Chapter- 1: INTRODUCTION - Complimentary 4 $0
STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC RESEARCH REPORTS
BCC ONLINE SERVICES
DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY 3 $250
Table Summary : GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH 2017
Figure Summary : GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, 2010-2017

Chapter- 3: OVERVIEW 32 $962
DEFINITION OF A VACCINE
DEFINITION OF IMMUNITY
HOW VACCINES WORK
IMPORTANCE OF VACCINES
HISTORY OF VACCINES
TYPES OF VACCINES
INFECTIOUS DISEASES PREVENTABLE BY VACCINES

Chapter- 4: REGULATORY ASPECTS 11 $331
REGULATORY ASPECTS
REGULATORY DEVELOPMENTS IN VACCINE-PREVENTABLE DISEASE PRODUCTS

Chapter- 5: PREVALENCE 6 $180
INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES

Chapter- 6: NEW DEVELOPMENTS 11 $331
NEW DEVELOPMENTS
NEW COLLABORATIVE TRIALS

Chapter- 7: GLOBAL MARKETS FOR HUMAN AND ANIMAL VACCINES 23 $691
VACCINE MARKET BY CATEGORY
MARKET BY TYPE
MARKET BY REGION
MARKET BY APPLICATION

Chapter- 8: MARKET ANALYSIS OF HUMAN VACCINES 60 $1803
MARKET BY TYPE
MARKET BY REGION
MARKET BY APPLICATION
INDUSTRY STRUCTURE

Chapter- 9: MARKET ANALYSIS OF ANIMAL VACCINES 21 $631
MARKET OVERVIEW
MARKET REVENUE
ANIMAL VACCINES
INDUSTRY STRUCTURE

Chapter- 10: PATENT ANALYSIS 37 $1112
PATENTS BY YEAR
PATENTS BY VACCINE TYPE
PATENTS BY ASSIGNEE'S COUNTRY
PATENTS BY COMPANY
PATENTS BY ASSIGNEE

Chapter- 11: CURRENT SITUATION 18 $541
ORGANIZATIONS DEDICATED TO GLOBAL IMMUNIZATIONS FOR HUMANS
UPDATE ON VACCINE-PREVENTABLE DISEASES IN HUMANS
NEW VACCINE TECHNOLOGIES AND PLATFORMS
FACTORS AFFECTING THE VACCINE MARKET
CURRENT DRIVERS OF THE VACCINE MARKET
ACQUISITIONS/COLLABORATIONS

Chapter- 12: COMPANY PROFILES 44 $1322
ABBOTT LABORATORIES
ADVAXIS
AERAS GLOBAL
ALPHAVAX INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BAXTER INTERNATIONAL INC.
BAYER HEALTHCARE ANIMAL HEALTH
BHARAT BIOTECH INTERNATIONAL LTD.
BIOLOGICAL E. LTD.
BIO-MANGUINHOS
BIOPROPERTIES
BOEHRINGER INGELHEIM GMBH
BUL BIO-NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB-NCIPD LTD.)
CADILA HEALTHCARE LTD.
CEVA SANTE ANIMALE
CHINA NATIONAL BIOTEC GROUP (CNBG)
COLORADO SERUM CO.
CRUCELL
CSL LTD.
ELANCO ANIMAL HEALTH
EMERGENT BIOSOLUTIONS INC.
FATRO SPA
GENVEC INC.
GEOVAX
GLAXOSMITHKLINE PLC
GREEN CROSS CORP.
HESKA CORP.
IMMUNE SOLUTIONS LTD.
INSTITUT PASTEUR DE DAKAR
INTERCELL AG
JAPAN BCG LABORATORY
LG LIFE SCIENCES
LOHMANN ANIMAL HEALTH INTERNATIONAL
MERCK & CO. INC.
MERIAL INC.
NIPPON BIOLOGICALS INC.
NOVARTIS AG
OKAIROS AG
PANACEA BIOTEC LTD.
PFENEX INC.
PFIZER
PROFECTUS BIOSCIENCES INC.
PT BIO FARMA
SANOFI PASTEUR
SERUM INSTITUTE OF INDIA LTD.
SHANTHA BIOTECHNICS LTD.
STATENS SERUM INSTITUT
VGX INTERNATIONAL INC.
VIRBAC
ZOETIS INC.

Chapter- 13: APPENDIX I 2 $60
ABBREVIATIONS

List of Tables

Summary Table : GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, THROUGH 2017
Table 1 : HISTORY OF VACCINES
Table 2 : TYPES OF ATTENUATED (LIVE) VACCINES
Table 3 : ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES
Table 4 : TYPES OF INACTIVATED (KILLED) VACCINES
Table 5 : ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES
Table 6 : TYPES OF TOXOID VACCINES
Table 7 : ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES
Table 8 : TYPES OF SUBUNIT VACCINES
Table 9 : ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES
Table 10 : TYPES OF CONJUGATE VACCINES
Table 11 : ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES
Table 12 : TYPES OF RECOMBINANT VECTOR VACCINES
Table 13 : ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES
Table 14 : TYPES OF DNA VACCINES
Table 15 : ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
Table 16 : VACCINE-PREVENTABLE HUMAN VIRAL DISEASES
Table 17 : VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES
Table 18 : VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN FOOD PRODUCING ANIMALS
Table 19 : VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN COMPANION ANIMALS
Table 20 : VACCINE-PREVENTABLE ANIMAL DISEASES FOUND IN OTHER ANIMALS
Table 21 : ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER ANIMALS
Table 22 : NATIONAL REGULATORY AUTHORITIES OF VACCINES ACROSS REGIONS
Table 23 : REVISIONS TO EXISTING VACCINES, 2010 THROUGH 2012
Table 24 : NEWLY APPROVED VACCINES, 2010 THROUGH 2012
Table 25 : GLOBAL VACCINE RECALLS, 2010 THROUGH 2012
Table 26 : REPORTED INCIDENCE DATA OF HUMAN DISEASES
Table 27 : IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES
Table 28 : REPORTED CASES OF VACCINE-PREVENTABLE HUMAN DISEASES WORLDWIDE, 2010 AND 2011
Table 29 : IMMUNIZATION COVERAGE OF VACCINE-PREVENTABLE HUMAN DISEASES WORLDWIDE, 2010 AND 2011
Table 30 : UPTAKE OF NEW AND UNDERUSED VACCINES, 2011
Table 31 : DEATHS OF CHILDREN GLOBALLY DUE TO DISEASES PREVENTABLE WITH VACCINES, 2011
Table 32 : ESTIMATED FUTURE DEATHS AVERTED WITH VACCINES, 2011-2020
Table 33 : HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF 2012
Table 34 : ALLIANCES, JOINT VENTURES AND AWARDS FOR THE DEVELOPMENT OF HUMAN AND ANIMAL VACCINES, 2010-2012
Table 35 : GLOBAL SALES OF VACCINES BY CATEGORY, THROUGH 2017
Table 36 : GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011
Table 37 : GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017
Table 38 : GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011
Table 39 : GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017
Table 40 : GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011
Table 41 : GLOBAL SALES OF VACCINES BY REGION, THROUGH 2017
Table 42 : GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011
Table 43 : GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, THROUGH 2017
Table 44 : GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011
Table 45 : MARKET SHARES OF TOP-SELLING VACCINES BY APPLICATION, 2011
Table 46 : GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2017
Table 47 : MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011
Table 48 : GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2017
Table 49 : MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011
Table 50 : GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION, THROUGH 2017
Table 51 : GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, THROUGH 2017
Table 52 : GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2017
Table 53 : GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, THROUGH 2017
Table 54 : GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2017
Table 55 : GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2017
Table 56 : GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, THROUGH 2017
Table 57 : HUMAN VACCINES BASED ON MICROORGANISM
Table 58 : GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/PNEUMOCOCCAL DISEASES, THROUGH 2017
Table 59 : MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/PNEUMOCOCCAL VACCINES, 2011
Table 60 : GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2017
Table 61 : MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2011
Table 62 : GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, THROUGH 2017
Table 63 : MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2011
Table 64 : GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES MARKET, THROUGH 2017
Table 65 : MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2011
Table 66 : GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, THROUGH 2017
Table 67 : MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2011
Table 68 : GLOBAL SALES OF HUMAN VACCINES IN HPV, THROUGH 2017
Table 69 : MARKET SHARES OF TOP-SELLING HPV VACCINES, 2011
Table 70 : GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, THROUGH 2017
Table 71 : MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2011
Table 72 : GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, THROUGH 2017
Table 73 : MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2011
Table 74 : GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011
Table 75 : LEADING MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES
Table 76 : MANUFACTURER/PROCESSORS' MARKET SHARES OF HUMAN VACCINE SALES, 2011
Table 77 : GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2010-2012
Table 78 : GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2017
Table 79 : GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, THROUGH 2017
Table 80 : GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, THROUGH 2017
Table 81 : GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH 2017
Table 82 : GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011
Table 83 : GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2017
Table 84 : MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011
Table 85 : LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES
Table 86 : MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE SALES, 2011
Table 87 : U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR, 2010-2012
Table 88 : U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE, 2010-2012
Table 89 : U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 90 : SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 91 : U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 92 : SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 93 : U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 94 : SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 95 : U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE’S COUNTRY, 2010-2012
Table 96 : SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 97 : U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 98 : SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 99 : U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 100 : SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 101 : U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Table 102 : SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010–2012
Table 103 : U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY COMPANY, 2010-2012
Table 104 : U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY COMPANY, 2010–2012
Table 105 : U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY, 2010-2012
Table 106 : U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY, 2010-2012
Table 107 : U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY COMPANY, 2010-2012
Table 108 : U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY COMPANY, 2010-2012
Table 109 : U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE TYPE, 2010-2012
Table 110 : U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE TYPE, 2010-2012
Table 111 : U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE, 2010-2012
Table 112 : U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE, 2010-2012
Table 113 : U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE, 2010-2012
Table 114 : U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE TYPE, 2010-2012
Table 115 : U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE TYPE, 2010-2012
Table 116 : GVAP GOAL LEVEL TARGETS
Table 117 : WHO-PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2012
Table 118 : VACCINE PRIORITIZATION, 2013-2014
Table 119 : VACCINE ACHIEVEMENTS AND CHALLENGES THROUGH 2012
Table 120 : WHO VACCINE RESEARCH AND PROGRESS

List of Figures

Summary Figure : GLOBAL SALES OF HUMAN AND ANIMAL VACCINES, 2010-2017
Figure 1 : GLOBAL SALES OF VACCINES BY CATEGORY, 2010-2017
Figure 2 : GLOBAL MARKET SHARES OF VACCINE SALES BY CATEGORY, 2011
Figure 3 : GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017
Figure 4 : GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011
Figure 5 : GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017
Figure 6 : GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011
Figure 7 : GLOBAL SALES OF VACCINES BY REGION, 2010-2017
Figure 8 : GLOBAL MARKET SHARES OF VACCINE SALES BY REGION, 2011
Figure 9 : GLOBAL SALES OF HUMAN VACCINES BY APPLICATION, 2010-2017
Figure 10 : GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011
Figure 11 : GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2010-2017
Figure 12 : MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2011
Figure 13 : GLOBAL SALES OF HUMAN VACCINES BY REGION, 2010-2017
Figure 14 : MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2011
Figure 15 : GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES BY REGION, 2010-2017
Figure 16 : GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, 2010-2017
Figure 17 : GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2010-2017
Figure 18 : GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, 2010-2017
Figure 19 : GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2010-2017
Figure 20 : GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2010-2017
Figure 21 : global market for other/combination vaccines by region, 2010-2017
Figure 22 : GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/PNEUMOCOCCAL DISEASES MARKET, 2010-2017
Figure 23 : GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2010-2017
Figure 24 : GLOBAL SALES OF HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, 2010-2017
Figure 25 : GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES MARKET, 2010-2017
Figure 26 : GLOBAL SALES OF HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2010-2017
Figure 27 : GLOBAL SALES OF HUMAN VACCINES IN HPV, 2010-2017
Figure 28 : GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS MARKET, 2010-2017
Figure 29 : GLOBAL SALES OF HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, 2010-2017
Figure 30 : GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2011
Figure 31 : MANUFACTURERS/PROCESSORS' MARKET SHARES OF HUMAN VACCINE SALES, 2011
Figure 32 : GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2010-2012
Figure 33 : GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2010-2017
Figure 34 : GLOBAL MARKET FR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, 2010-2017
Figure 35 : GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, 2010-2017
Figure 36 : GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, 2010-2017
Figure 37 : GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2011
Figure 38 : GLOBAL SALES OF ANIMAL VACCINES BY REGION, 2010-2017
Figure 39 : MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2011
Figure 40 : MANUFACTURER/PROCESSORS' MARKET SHARES OF ANIMAL VACCINE SALES, 2011
Figure 41 : U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY YEAR, 2010-2012
Figure 42 : U.S. PATENTS GRANTED FOR HUMAN AND ANIMAL VACCINES BY TYPE, 2010-2012
Figure 43 : U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 44 : SHARES OF U.S. PATENTS ON ATTENUATED (LIVE) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 45 : U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 46 : SHARES OF U.S. PATENTS ON INACTIVATED (KILLED) VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 47 : U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 48 : SHARES OF U.S. PATENTS ON TOXOID VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 49 : U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 50 : SHARES OF U.S. PATENTS ON SUBUNIT VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 51 : U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 52 : SHARES OF U.S. PATENTS ON CONJUGATE VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 53 : U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 54 : SHARES OF U.S. PATENTS ON RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 55 : U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 56 : SHARES OF U.S. PATENTS ON OTHER/COMBINATION VACCINES BY ASSIGNEE'S COUNTRY, 2010-2012
Figure 57 : U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY COMPANY, 2010-2012
Figure 58 : U.S. PATENTS GRANTED ON INACTIVATED (KILLED) VACCINES BY COMPANY, 2010-2012
Figure 59 : U.S. PATENTS GRANTED ON SUBUNIT VACCINES BY COMPANY, 2010-2012
Figure 60 : U.S. PATENTS GRANTED ON CONJUGATE VACCINES BY COMPANY, 2010-2012
Figure 61 : U.S. PATENTS GRANTED ON RECOMBINANT/RDNA/DNA VACCINES BY COMPANY, 2010-2012
Figure 62 : U.S. PATENTS GRANTED ON OTHER/COMBINATION VACCINES BY COMPANY, 2010-2012
Figure 63 : U.S. PATENTS GRANTED FOR ATTENUATED (LIVE) VACCINES BY ASSIGNEE TYPE, 2010-2012
Figure 64 : U.S. PATENTS GRANTED FOR INACTIVATED (KILLED) VACCINES BY ASSIGNEE TYPE, 2010-2012
Figure 65 : U.S. PATENTS GRANTED FOR TOXOID VACCINES BY ASSIGNEE TYPE, 2010-2012
Figure 66 : U.S. PATENTS GRANTED FOR SUBUNIT VACCINES BY ASSIGNEE TYPE, 2010-2012
Figure 67 : U.S. PATENTS GRANTED FOR CONJUGATE VACCINES BY ASSIGNEE TYPE, 2010-2012
Figure 68 : U.S. PATENTS GRANTED FOR RECOMBINANT/RDNA/DNA VACCINES BY ASSIGNEE TYPE, 2010-2012
Figure 69 : U.S. PATENTS GRANTED FOR OTHER/COMBINATION VACCINES BY ASSIGNEE TYPE, 2010-2012

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 168817, price: INR 405010, BCC Research

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online